CDX2 (Homeobox protein CDX-2) variants and mutations
CDX2 (also known as Homeobox protein CDX-2) is a human protein-coding gene encoding a homeobox protein CDX-2 protein. It establishes and maintains intestinal epithelial identity by activating intestine-specific transcriptional programs. Loss or altered expression can accompany gastrointestinal tumor progression, while retained expression is widely used as a marker of intestinal differentiation. This analysis covers 684 CDX2 variants and mutations. Of these, 96% have computational variant effect predictions. Disease context includes neurodegenerative disease, multiple congenital anomalies/dysmorphic syndrome-intellectual disability, and lung carcinoma. Example CDX2 variants include Y2*, V3M, and S4R.
Variant analysis overview
- Gene: CDX2
- Protein: Homeobox protein CDX-2
- UniProt accession: Q99626
- Organism: Homo sapiens
- Variants analyzed: 684
- Variant scope: all variants
- Completed: 2026-07-30
Variant and mutation evidence
- Variant composition: 378 unspecified-consequence records; 1 stop lost; 1 stop retained variant; 114 synonymous variants; 7 frameshift variants; 160 missense variants; 10 in-frame deletions; 1 in-frame insertions; 9 stop-gained variants; 3 substitution
- Prediction scores: 660 variants have prediction scores (96% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodegenerative disease, multiple congenital anomalies/dysmorphic syndrome-intellectual disability, lung carcinoma, gastrointestinal stromal tumor, nodular malignant melanoma, superficial spreading melanoma, endometrial endometrioid adenocarcinoma, breast carcinoma, gastric carcinoma, esophageal adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma.
Protein structure and variant hotspots
- Protein features: 2 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CDX2 variants
Examples include Y2*, V3M, S4R, Y5C, L6F, L7P, D8E, D8G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Y2* (p.Tyr2Ter), TOPMed rs1437661942, gnomAD rs1437661942, CADD 37.00
- V3M (p.Val3Met), gnomAD rs947361705, REVEL 0.56, MetaLR 0.81
- S4R (p.Ser4Arg), NCI-TCGA TCGA novel, REVEL 0.54, MetaLR 0.81, Variant assessed as somatic; high impact.
- Y5C (p.Tyr5Cys), NCI-TCGA Cosmic COSV1011, MetaLR 0.59, MetaSVM 0.09, Variant assessed as somatic; moderate impact.
- L6F (p.Leu6Phe), gnomAD rs1320769577, REVEL 0.49, MetaLR 0.86
- L7P (p.Leu7Pro), gnomAD rs1456435972, REVEL 0.92, MetaLR 0.89, Uncertain significance, not specified
- D8E (p.Asp8Glu), rs1217840490, ClinGen CA387641746, ClinVar RCV004325026, TOPMed rs1217840490, REVEL 0.28, MetaLR 0.39, Uncertain significance, not specified
- D8G (p.Asp8Gly), ExAC rs759160901, TOPMed rs759160901, gnomAD rs759160901, REVEL 0.78, MetaLR 0.77
- D10V (p.Asp10Val), Ensembl rs2137546361, MetaLR 0.81, MetaSVM 0.78
- V11L (p.Val11Leu), TOPMed rs1257411911, gnomAD rs1257411911, REVEL 0.29, MetaLR 0.56
- S12C (p.Ser12Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M13I (p.Met13Ile), ExAC rs770731321, TOPMed rs770731321, gnomAD rs770731321, REVEL 0.36, MetaLR 0.32
- M13T (p.Met13Thr), Ensembl rs1869500059, MetaLR 0.22, MetaSVM -0.70
- P15S (p.Pro15Ser), TOPMed rs1191697722, gnomAD rs1191697722, REVEL 0.33, MetaLR 0.32
- P15T (p.Pro15Thr), TOPMed rs1191697722, gnomAD rs1191697722, REVEL 0.57, MetaLR 0.44
- S16I (p.Ser16Ile), NCI-TCGA TCGA novel, MetaLR 0.13, MetaSVM -0.96, Variant assessed as somatic; moderate impact.
- S16N (p.Ser16Asn), gnomAD rs1248455878, REVEL 0.09, MetaLR 0.06
- V18A (p.Val18Ala), gnomAD rs1258550217, REVEL 0.09, MetaLR 0.09
- V18M (p.Val18Met), gnomAD rs975106537, REVEL 0.10, MetaLR 0.12
- R19G (p.Arg19Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R19H (p.Arg19His), gnomAD rs1278782770, REVEL 0.42, MetaLR 0.31
- R19S (p.Arg19Ser), gnomAD rs1344424042, REVEL 0.25, MetaLR 0.25
- H20Q (p.His20Gln), ESP rs142407700, ExAC rs142407700, TOPMed rs142407700, gnomAD rs142407700, REVEL 0.11, MetaLR 0.12
- H20R (p.His20Arg), ExAC rs777630450, TOPMed rs777630450, gnomAD rs777630450, REVEL 0.07, MetaLR 0.08
- S21C (p.Ser21Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G22D (p.Gly22Asp), gnomAD rs1227738305, REVEL 0.52, MetaLR 0.67
- G22S (p.Gly22Ser), Ensembl rs1019333820, REVEL 0.21, MetaLR 0.38
- G23S (p.Gly23Ser), TOPMed rs993889248, gnomAD rs993889248, REVEL 0.20, MetaLR 0.14
- L24F (p.Leu24Phe), TOPMed rs1324248754, gnomAD rs1324248754, REVEL 0.21, MetaLR 0.23
- L24P (p.Leu24Pro), TOPMed rs1869496085, REVEL 0.33, MetaLR 0.23
- N25K (p.Asn25Lys), NCI-TCGA Cosmic COSV1011, REVEL 0.21, MetaLR 0.23, Variant assessed as somatic; moderate impact.
- N25S (p.Asn25Ser), gnomAD rs1396059209, REVEL 0.14, MetaLR 0.11
- N25T (p.Asn25Thr), gnomAD rs1396059209, REVEL 0.20, MetaLR 0.24
- A27E (p.Ala27Glu), ExAC rs750529483, TOPMed rs750529483, gnomAD rs750529483, REVEL 0.18, MetaLR 0.12
- P28L (p.Pro28Leu), ExAC rs781197054, TOPMed rs781197054, gnomAD rs781197054, REVEL 0.31, MetaLR 0.19
- P28Q (p.Pro28Gln), ExAC rs781197054, TOPMed rs781197054, gnomAD rs781197054, REVEL 0.32, MetaLR 0.19
- P28R (p.Pro28Arg), ExAC rs781197054, TOPMed rs781197054, gnomAD rs781197054
- P28S (p.Pro28Ser), gnomAD rs1431625593, REVEL 0.21, MetaLR 0.17
- P28T (p.Pro28Thr), gnomAD rs1431625593
- Q29H (p.Gln29His), ESP rs375192541, ExAC rs375192541, TOPMed rs375192541, gnomAD rs375192541
- V32L (p.Val32Leu), ExAC rs751662963, gnomAD rs751662963, REVEL 0.33, MetaLR 0.22
- S33N (p.Ser33Asn), ExAC rs763279091, gnomAD rs763279091, REVEL 0.12, MetaLR 0.22
- S33T (p.Ser33Thr), ExAC rs763279091, gnomAD rs763279091, REVEL 0.10, MetaLR 0.14
- P34A (p.Pro34Ala), ExAC rs753078414, TOPMed rs753078414, gnomAD rs753078414
- P34S (p.Pro34Ser), ExAC rs753078414, TOPMed rs753078414, gnomAD rs753078414, REVEL 0.06, MetaLR 0.08
- P35A (p.Pro35Ala), 1000Genomes rs148740542, ESP rs148740542, ExAC rs148740542, TOPMed rs148740542, REVEL 0.21, MetaLR 0.14, Uncertain significance
- P35L (p.Pro35Leu), ExAC rs760227069, TOPMed rs760227069, gnomAD rs760227069, REVEL 0.27, MetaLR 0.32
- P35Q (p.Pro35Gln), ExAC rs760227069, TOPMed rs760227069, gnomAD rs760227069, REVEL 0.23, MetaLR 0.26
- P35S (p.Pro35Ser), 1000Genomes rs148740542, ESP rs148740542, ExAC rs148740542, TOPMed rs148740542, REVEL 0.24, MetaLR 0.32, Uncertain significance
- P35T (p.Pro35Thr), rs148740542, ClinGen CA6927991, ClinVar RCV004199991, 1000Genomes rs148740542, REVEL 0.28, MetaLR 0.33, Uncertain significance, not specified
- Q36R (p.Gln36Arg), rs1213138909, ClinGen CA387641300, ClinVar RCV004264559, TOPMed rs1213138909, REVEL 0.27, MetaLR 0.23, Uncertain significance, not specified
- Y37C (p.Tyr37Cys), NCI-TCGA TCGA novel, MetaLR 0.40, MetaSVM -0.20, Variant assessed as somatic; moderate impact.
- Y37H (p.Tyr37His), ExAC rs772797601, TOPMed rs772797601, gnomAD rs772797601, REVEL 0.47, MetaLR 0.40
- P38T (p.Pro38Thr), gnomAD rs1285569828, REVEL 0.07, MetaLR 0.09
- D39Y (p.Asp39Tyr), gnomAD rs1245118789, REVEL 0.27, MetaLR 0.29
- G41D (p.Gly41Asp), rs1339366385, ClinGen CA387641223, ClinVar RCV004144980, TOPMed rs1339366385, REVEL 0.15, MetaLR 0.17, Uncertain significance, not specified
- G42D (p.Gly42Asp), gnomAD rs1411143537, REVEL 0.24, MetaLR 0.17
- G42R (p.Gly42Arg), TOPMed rs1869490676
- Y43C (p.Tyr43Cys), ExAC rs771731984, gnomAD rs771731984, REVEL 0.70, MetaLR 0.45
- H44Q (p.His44Gln), TOPMed rs1307362699, gnomAD rs1307362699, REVEL 0.28, MetaLR 0.19
- A46E (p.Ala46Glu), rs747931887, ClinGen CA6927987, ClinVar RCV004311660, ExAC rs747931887, REVEL 0.16, MetaLR 0.10, Uncertain significance, not specified
- A46P (p.Ala46Pro), Ensembl rs1026510818
- A47T (p.Ala47Thr), TOPMed rs1869489575, REVEL 0.06, MetaLR 0.09
- A47V (p.Ala47Val), TOPMed rs1869489397, REVEL 0.07, MetaLR 0.09
- A49G (p.Ala49Gly), TOPMed rs1164040208, gnomAD rs1164040208, REVEL 0.12, MetaLR 0.04
- A49T (p.Ala49Thr), TOPMed rs934737987, gnomAD rs934737987, REVEL 0.13, MetaLR 0.05
- A50E (p.Ala50Glu), NCI-TCGA Cosmic COSV6682, REVEL 0.43, MetaLR 0.44, Variant assessed as somatic; moderate impact.
- A50P (p.Ala50Pro), Ensembl rs1593186089
- A50V (p.Ala50Val), Ensembl rs1593186083, REVEL 0.29, MetaLR 0.46
- A51T (p.Ala51Thr), ExAC rs768601101, TOPMed rs768601101, gnomAD rs768601101, REVEL 0.22, MetaLR 0.43
- A52V (p.Ala52Val), gnomAD rs1184352216, REVEL 0.26, MetaLR 0.37
- A53E (p.Ala53Glu), gnomAD rs1472976227, REVEL 0.23, MetaLR 0.46
- N54K (p.Asn54Lys), Ensembl rs1869487367, REVEL 0.12, MetaLR 0.17
- D56Y (p.Asp56Tyr), rs944439728, []
- S57I (p.Ser57Ile), TOPMed rs1869487192, gnomAD rs1869487192, REVEL 0.05, MetaLR 0.09
- A58E (p.Ala58Glu), TOPMed rs1453653936, gnomAD rs1453653936, REVEL 0.12, MetaLR 0.13
- P61S (p.Pro61Ser), rs1210053674, NCI-TCGA Cosmic COSV6682, gnomAD rs1210053674, REVEL 0.08, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- G62E (p.Gly62Glu), 1000Genomes rs541454452, ExAC rs541454452, gnomAD rs541454452, REVEL 0.25, MetaLR 0.14
- P63L (p.Pro63Leu), ExAC rs747093473, TOPMed rs747093473, gnomAD rs747093473, REVEL 0.14, MetaLR 0.21
- P63T (p.Pro63Thr), TOPMed rs1229659905, gnomAD rs1229659905, REVEL 0.08, MetaLR 0.11
- W65C (p.Trp65Cys), gnomAD rs1278849023, REVEL 0.47, MetaLR 0.50
- P66L (p.Pro66Leu), TOPMed rs965288118, REVEL 0.10, MetaLR 0.06
- P66Q (p.Pro66Gln), TOPMed rs965288118, REVEL 0.13, MetaLR 0.12
- A68G (p.Ala68Gly), TOPMed rs1351392007, gnomAD rs1351392007, REVEL 0.17, MetaLR 0.07, Uncertain significance, not specified
- A71S (p.Ala71Ser), TOPMed rs938780507, gnomAD rs938780507, REVEL 0.10, MetaLR 0.08
- A71T (p.Ala71Thr), NCI-TCGA TCGA novel, TOPMed rs938780507, gnomAD rs938780507, REVEL 0.11, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- P72S (p.Pro72Ser), TOPMed rs1161680382, gnomAD rs1161680382, REVEL 0.27, MetaLR 0.16
- L73P (p.Leu73Pro), TOPMed rs1275910356
- W77L (p.Trp77Leu), Ensembl rs2137545686
- W77R (p.Trp77Arg), gnomAD rs1175984027, MetaLR 0.50, MetaSVM 0.01
- Y80* (p.Tyr80Ter), ExAC rs754463501, gnomAD rs754463501, CADD 35.00
- Y80C (p.Tyr80Cys), 1000Genomes rs546556192, REVEL 0.46, MetaLR 0.38
- Y80S (p.Tyr80Ser), 1000Genomes rs546556192, MetaLR 0.38, MetaSVM -0.40
- A81E (p.Ala81Glu), ExAC rs760152351, gnomAD rs760152351, REVEL 0.19, MetaLR 0.13
- A81P (p.Ala81Pro), ExAC rs766979635
- G83E (p.Gly83Glu), gnomAD rs1869481410, REVEL 0.31, MetaLR 0.22
- G84S (p.Gly84Ser), TOPMed rs903262296, gnomAD rs903262296, REVEL 0.09, MetaLR 0.06, Uncertain significance, not specified
- A85G (p.Ala85Gly), TOPMed rs1458282607, MetaLR 0.05, MetaSVM -1.01
- A86S (p.Ala86Ser), TOPMed rs1329227286, gnomAD rs1329227286, REVEL 0.06, MetaLR 0.05, Uncertain significance, not specified
- A86T (p.Ala86Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A86V (p.Ala86Val), Ensembl rs1869479874, REVEL 0.12, MetaLR 0.08
- A87G (p.Ala87Gly), TOPMed rs1200799851, gnomAD rs1200799851, REVEL 0.09, MetaLR 0.06
- A87P (p.Ala87Pro), gnomAD rs1283009167
- A87S (p.Ala87Ser), gnomAD rs1283009167, REVEL 0.13, MetaLR 0.05
- A88S (p.Ala88Ser), rs947168191, ClinGen CA247255924, ClinVar RCV004184221, 1000Genomes rs947168191, REVEL 0.09, MetaLR 0.07, Uncertain significance, not specified
- N90D (p.Asn90Asp), Ensembl rs1566038344, REVEL 0.12, MetaLR 0.07
- N90H (p.Asn90His), Ensembl rs1566038344, REVEL 0.04, MetaLR 0.06
- N90K (p.Asn90Lys), TOPMed rs1368580705, gnomAD rs1368580705, REVEL 0.13, MetaLR 0.06, Uncertain significance, not specified
- V92A (p.Val92Ala), gnomAD rs1458027587, REVEL 0.09, MetaLR 0.04
- V92L (p.Val92Leu), TOPMed rs1465691880, REVEL 0.05, MetaLR 0.06
- V92M (p.Val92Met), TOPMed rs1465691880, REVEL 0.13, MetaLR 0.11
- A93S (p.Ala93Ser), NCI-TCGA Cosmic COSV1011, MetaLR 0.44, MetaSVM -0.68, Variant assessed as somatic; moderate impact.
- A93T (p.Ala93Thr), NCI-TCGA Cosmic COSV1011, REVEL 0.26, MetaLR 0.57, Variant assessed as somatic; moderate impact.
- H94R (p.His94Arg), TOPMed rs1869476090, REVEL 0.28, MetaLR 0.51
- G95C (p.Gly95Cys), TOPMed rs1416249492, gnomAD rs1416249492, REVEL 0.36, MetaLR 0.75
- G95R (p.Gly95Arg), TOPMed rs1416249492, gnomAD rs1416249492
- G95S (p.Gly95Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L96F (p.Leu96Phe), ExAC rs767105649, TOPMed rs767105649, gnomAD rs767105649, REVEL 0.32, MetaLR 0.57
- N97H (p.Asn97His), Ensembl rs2137545466
- N97S (p.Asn97Ser), TOPMed rs1869475139, REVEL 0.04, MetaLR 0.07
- G98C (p.Gly98Cys), ESP rs367878628, TOPMed rs367878628, gnomAD rs367878628, REVEL 0.23, MetaLR 0.20
- G98S (p.Gly98Ser), ESP rs367878628, TOPMed rs367878628, gnomAD rs367878628, REVEL 0.07, MetaLR 0.06
- G98V (p.Gly98Val), Ensembl rs1869474583, REVEL 0.20, MetaLR 0.12
- S100F (p.Ser100Phe), gnomAD rs1250362747, REVEL 0.23, MetaLR 0.21
- P101Q (p.Pro101Gln), TOPMed rs1869473418
- P101R (p.Pro101Arg), TOPMed rs1869473418, REVEL 0.30, MetaLR 0.30
- A103S (p.Ala103Ser), rs1190093290, ClinGen CA387640531, ClinVar RCV004431100, REVEL 0.05, MetaLR 0.10, Uncertain significance, not specified
- A103T (p.Ala103Thr), TOPMed rs1190093290, gnomAD rs1190093290, REVEL 0.06, MetaLR 0.06
- A104V (p.Ala104Val), NCI-TCGA Cosmic COSV6682, REVEL 0.07, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- M105I (p.Met105Ile), Ensembl rs1869472453, REVEL 0.10, MetaLR 0.08
- G106E (p.Gly106Glu), rs754672457, []
- Y107H (p.Tyr107His), TOPMed rs914501213, gnomAD rs914501213, REVEL 0.10, MetaLR 0.13
- S108G (p.Ser108Gly), Ensembl rs1869471559, MetaLR 0.60, MetaSVM -0.18
- S108N (p.Ser108Asn), Ensembl rs878994685, REVEL 0.33, MetaLR 0.54
- S109R (p.Ser109Arg), ExAC rs376274339, TOPMed rs376274339, gnomAD rs376274339, REVEL 0.14, MetaLR 0.14
- S109A (p.Ser109Ala), rs773759361, []
- A111G (p.Ala111Gly), gnomAD rs1233529098, MetaLR 0.09, MetaSVM -1.03
- A111S (p.Ala111Ser), TOPMed rs1279218920, gnomAD rs1279218920, REVEL 0.06, MetaLR 0.05
- A111T (p.Ala111Thr), TOPMed rs1279218920, gnomAD rs1279218920, REVEL 0.04, MetaLR 0.06
- D112H (p.Asp112His), TOPMed rs1345464021, gnomAD rs1345464021, REVEL 0.20, MetaLR 0.20, Uncertain significance
- D112N (p.Asp112Asn), rs1345464021, ClinGen CA387640428, ClinVar RCV004159109, TOPMed rs1345464021, REVEL 0.09, MetaLR 0.17, Uncertain significance, not specified
- D112Y (p.Asp112Tyr), TOPMed rs1345464021, gnomAD rs1345464021, REVEL 0.09, MetaLR 0.13, Uncertain significance
- Y113N (p.Tyr113Asn), TOPMed rs961118689, gnomAD rs961118689, REVEL 0.34, MetaLR 0.20
- H114Q (p.His114Gln), rs145287912, ClinGen CA6927968, ClinVar RCV004431101, ESP rs145287912, REVEL 0.08, MetaLR 0.06, Uncertain significance, not specified
- H114R (p.His114Arg), TOPMed rs1869469940, REVEL 0.14, MetaLR 0.08
- P115L (p.Pro115Leu), TOPMed rs1361456473, gnomAD rs1361456473, REVEL 0.08, MetaLR 0.08
- P115T (p.Pro115Thr), rs2500275452, ClinGen CA387640394, ClinVar RCV004174353, REVEL 0.08, MetaLR 0.06, Uncertain significance, not specified
- H116N (p.His116Asn), Ensembl rs942386047, REVEL 0.09, MetaLR 0.07
- H116P (p.His116Pro), ExAC rs775459380, TOPMed rs775459380, gnomAD rs775459380, REVEL 0.23, MetaLR 0.06, Uncertain significance, not specified
- H116R (p.His116Arg), ExAC rs775459380, TOPMed rs775459380, gnomAD rs775459380, REVEL 0.14, MetaLR 0.08
- H117D (p.His117Asp), gnomAD rs1359855388, REVEL 0.15, MetaLR 0.09
- H117Q (p.His117Gln), ESP rs376360900, ExAC rs376360900, TOPMed rs376360900, gnomAD rs376360900, REVEL 0.06, MetaLR 0.05
- H117Y (p.His117Tyr), gnomAD rs1359855388, REVEL 0.09, MetaLR 0.13
- H118N (p.His118Asn), TOPMed rs1433460970, gnomAD rs1433460970, REVEL 0.12, MetaLR 0.09
- H118Q (p.His118Gln), ExAC rs747093596, TOPMed rs747093596, gnomAD rs747093596, REVEL 0.08, MetaLR 0.07, Uncertain significance, not specified
- H118Y (p.His118Tyr), TOPMed rs1433460970, gnomAD rs1433460970, REVEL 0.12, MetaLR 0.08
- P119A (p.Pro119Ala), gnomAD rs1351175619, REVEL 0.22, MetaLR 0.46
- P119S (p.Pro119Ser), gnomAD rs1351175619, REVEL 0.23, MetaLR 0.46
- H120P (p.His120Pro), TOPMed rs1392577295, gnomAD rs1392577295, REVEL 0.28, MetaLR 0.50
- H121Q (p.His121Gln), TOPMed rs986416792, gnomAD rs986416792, REVEL 0.28, MetaLR 0.36
- H121R (p.His121Arg), ExAC rs777861598, gnomAD rs777861598, REVEL 0.30, MetaLR 0.45
- H121Y (p.His121Tyr), gnomAD rs1169547453, REVEL 0.29, MetaLR 0.44
- P123L (p.Pro123Leu), ExAC rs758562806, TOPMed rs758562806, gnomAD rs758562806, REVEL 0.32, MetaLR 0.56, Uncertain significance, not specified
- P123R (p.Pro123Arg), ExAC rs758562806, TOPMed rs758562806, gnomAD rs758562806, MetaLR 0.67, MetaSVM -0.14, Uncertain significance
- H125P (p.His125Pro), Ensembl rs2137545124, REVEL 0.32, MetaLR 0.50
- H125Y (p.His125Tyr), TOPMed rs901843762, REVEL 0.26, MetaLR 0.63
- P126A (p.Pro126Ala), Ensembl rs1869464273
- P126L (p.Pro126Leu), Ensembl rs1593185791, REVEL 0.26, MetaLR 0.56
- A127D (p.Ala127Asp), TOPMed rs910722437, gnomAD rs910722437, REVEL 0.20, MetaLR 0.50, Uncertain significance, not specified
- A128D (p.Ala128Asp), TOPMed rs930891731, gnomAD rs930891731, REVEL 0.38, MetaLR 0.52
- A129S (p.Ala129Ser), gnomAD rs1293678984, REVEL 0.08, MetaLR 0.06
- A129T (p.Ala129Thr), gnomAD rs1293678984, REVEL 0.04, MetaLR 0.07
- A129V (p.Ala129Val), 1000Genomes rs537506510, ExAC rs537506510, gnomAD rs537506510, REVEL 0.08, MetaLR 0.08
- p.Ala129 Ala153del, gnomAD 13-27968546-TCGGC, CADD 18.30
- P130A (p.Pro130Ala), TOPMed rs1379964377, gnomAD rs1379964377, REVEL 0.07, MetaLR 0.07, Uncertain significance, not specified
- P130T (p.Pro130Thr), TOPMed rs1379964377, gnomAD rs1379964377, REVEL 0.07, MetaLR 0.06
- S131P (p.Ser131Pro), TOPMed rs1869462209
- S131S (p.Ser131Ser), gnomAD 13-27968614-G-T, CADD 6.00
- S131Y (p.Ser131Tyr), gnomAD 13-27968615-G-T, REVEL 0.06, MetaLR 0.08
- S131F (p.Ser131Phe), gnomAD 13-27968615-G-A, REVEL 0.06, MetaLR 0.10
Public CDX2 analysis runs
- CDX2 analysis run — CDX2 (684 variants) — completed 2026-07-30